newsfilter
← Latest News
GlobeNewswire·

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical